Cargando…
Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori
AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942845/ https://www.ncbi.nlm.nih.gov/pubmed/31933634 http://dx.doi.org/10.1155/2019/9251879 |
_version_ | 1783484783008940032 |
---|---|
author | Zhang, Lingyun Lan, Yu Wang, Qi Zhang, Yuexia Si, Xiaobei |
author_facet | Zhang, Lingyun Lan, Yu Wang, Qi Zhang, Yuexia Si, Xiaobei |
author_sort | Zhang, Lingyun |
collection | PubMed |
description | AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June 2017 and October 2018. Patients were randomly divided into a minocycline/amoxicillin (RMAB) group, a minocycline/metronidazole (RMMB) group, or an amoxicillin/clarithromycin (RACB) group, and all groups received a combined treatment approach with rabeprazole and bismuth to create a quadruple regimen for 14 days. A 3 to 5-day follow-up was adopted to evaluate the safety and compliance of medications after medicine administration. (13)C-urea breath test was performed to confirm the eradication of H. pylori 4-12 weeks after therapy. RESULTS: No significant differences were observed at baseline data among the three groups (p > 0.05). Based on the intent-to-treat analysis, the eradication rates of the RMAB group, RMMB group, and RACB control group were 85.7% (102/119), 77.1% (91/118), and 71.7% (86/120), respectively, with significant difference (χ(2) = 7.015, p = 0.030). According to per protocol analysis, the eradication rates of RMAB group, RMMB group, and RACB group were 89.5% (102/114), 84.3% (91/108), and 76.8% (86/112), respectively, with statistically significant differences (χ(2) = 6.673, p = 0.036). The eradication rates of the RMAB group and RACB group were significantly different (p < 0.05). The overall incidences of adverse events in the three groups were 30.0%, 37.5%, and 40.0%, respectively (p > 0.05). Nausea, epigastric discomfort, and dizziness were more obvious in patients in the RMMB group compared to the other two groups (p < 0.05). Moreover, two patients discontinued due to severe dizziness and nausea in the RMMB group. A taste disorder was more prominent in patients in the RACB group compared to patients in the other two groups (p < 0.05), and one patient discontinued because of the bitterness in the mouth. Soon after discontinuation of the medicine, all adverse events disappeared. Conclusion. The bismuth quadruple regimen using minocycline/amoxicillin showed a better eradication effect with fewer side effects in patients with untreated H. pylori infections. The bismuth quadruple regimen with minocycline/metronidazole had a good eradication effect with more obvious side effects and might be recommended to patients with penicillin allergy. |
format | Online Article Text |
id | pubmed-6942845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-69428452020-01-13 Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori Zhang, Lingyun Lan, Yu Wang, Qi Zhang, Yuexia Si, Xiaobei Gastroenterol Res Pract Research Article AIM: To evaluate the eradication rate, safety, and compliance of minocycline-containing bismuth quadruple regimens in patients with an untreated Helicobacter pylori (H. pylori) infection. METHODS: A total of 360 patients with an untreated H. pylori infection were enrolled in this study between June 2017 and October 2018. Patients were randomly divided into a minocycline/amoxicillin (RMAB) group, a minocycline/metronidazole (RMMB) group, or an amoxicillin/clarithromycin (RACB) group, and all groups received a combined treatment approach with rabeprazole and bismuth to create a quadruple regimen for 14 days. A 3 to 5-day follow-up was adopted to evaluate the safety and compliance of medications after medicine administration. (13)C-urea breath test was performed to confirm the eradication of H. pylori 4-12 weeks after therapy. RESULTS: No significant differences were observed at baseline data among the three groups (p > 0.05). Based on the intent-to-treat analysis, the eradication rates of the RMAB group, RMMB group, and RACB control group were 85.7% (102/119), 77.1% (91/118), and 71.7% (86/120), respectively, with significant difference (χ(2) = 7.015, p = 0.030). According to per protocol analysis, the eradication rates of RMAB group, RMMB group, and RACB group were 89.5% (102/114), 84.3% (91/108), and 76.8% (86/112), respectively, with statistically significant differences (χ(2) = 6.673, p = 0.036). The eradication rates of the RMAB group and RACB group were significantly different (p < 0.05). The overall incidences of adverse events in the three groups were 30.0%, 37.5%, and 40.0%, respectively (p > 0.05). Nausea, epigastric discomfort, and dizziness were more obvious in patients in the RMMB group compared to the other two groups (p < 0.05). Moreover, two patients discontinued due to severe dizziness and nausea in the RMMB group. A taste disorder was more prominent in patients in the RACB group compared to patients in the other two groups (p < 0.05), and one patient discontinued because of the bitterness in the mouth. Soon after discontinuation of the medicine, all adverse events disappeared. Conclusion. The bismuth quadruple regimen using minocycline/amoxicillin showed a better eradication effect with fewer side effects in patients with untreated H. pylori infections. The bismuth quadruple regimen with minocycline/metronidazole had a good eradication effect with more obvious side effects and might be recommended to patients with penicillin allergy. Hindawi 2019-12-18 /pmc/articles/PMC6942845/ /pubmed/31933634 http://dx.doi.org/10.1155/2019/9251879 Text en Copyright © 2019 Lingyun Zhang et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhang, Lingyun Lan, Yu Wang, Qi Zhang, Yuexia Si, Xiaobei Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title | Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title_full | Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title_fullStr | Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title_full_unstemmed | Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title_short | Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori |
title_sort | application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of helicobacter pylori |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942845/ https://www.ncbi.nlm.nih.gov/pubmed/31933634 http://dx.doi.org/10.1155/2019/9251879 |
work_keys_str_mv | AT zhanglingyun applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori AT lanyu applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori AT wangqi applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori AT zhangyuexia applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori AT sixiaobei applicationofminocyclinecontainingbismuthquadrupletherapiesasfirstlineregimensinthetreatmentofhelicobacterpylori |